quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile

View original at finance.yahoo.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The most followed view sees Barclays as 27.2% undervalued with a fair value of £5.30 versus current price of £3.8545

    60% confidence
  • Predictable, multi-year structural hedge income and net interest income momentum, supported by disciplined deposit management, asset repricing and loan growth, will underpin consistent NII growth and support progressive shareholder distributions, enhancing earnings visibility

    60% confidence
  • Barclays is trading at an intrinsic discount of about 58% with a value score of 6

    60% confidence
  • Tougher competition for UK deposits, or setbacks integrating acquisitions like Tesco Bank or a potential Evelyn Partners deal, could quickly challenge the upbeat valuation view

    60% confidence

Data points we hold from this source

Barclays · one year total shareholder return30 percent
Barclays · thirty day return-16 percent
Barclays · three month return-18 percent
Barclays · value score6 score
Barclays · year to date return-20 percent
Barclays · fair value5.30 GBP
Barclays · five year total shareholder return150 percent
Barclays · intrinsic discount58 percent
Barclays · one month return-16 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile — Source | Via News | pt.VIA.NEWS